Aurinia Pharmaceuticals’ (AUPH) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a report released on Monday morning, Benzinga reports. They currently have a $10.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright restated a buy rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ AUPH opened at $7.13 on Monday. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.05. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -16.58 and a beta of 1.44. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average is $6.09 and its 200-day moving average is $5.56.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. The firm had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The company’s revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.08) earnings per share. Equities research analysts predict that Aurinia Pharmaceuticals will post 0.13 EPS for the current year.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the sale, the insider now owns 456,338 shares in the company, valued at approximately $2,423,154.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $30,000. Tidemark LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $39,000. Banque Cantonale Vaudoise raised its holdings in Aurinia Pharmaceuticals by 126.6% during the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 5,410 shares in the last quarter. Virtu Financial LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at approximately $78,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Aurinia Pharmaceuticals during the second quarter valued at approximately $84,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.